MASH drug developers rise as FDA accepts lenient trial requirement
Source: SeekingAlpha
2025-08-27 13:44:42 ET
More on Viking Therapeutics, Altimmune, etc.
- Viking: Still On Track, But The Compass Needs Recalibration
- Viking Therapeutics: Panic Creates Opportunity
- Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell
- Inventiva surges as Piper Sandler issues bullish view citing lead asset
- Is Viking Therapeutics stock a bargain after this week’s sell-off?
Read the full article on Seeking Alpha
For further details see:
MASH drug developers rise as FDA accepts lenient trial requirement
GENFIT S.A.
NASDAQ: GNFT
GNFT Trading
7.71% G/L:
$4.61 Last:
26,010 Volume:
$4.38 Open:
GNFT Latest News
GNFT Stock Data
$242,481,497
47,631,365
N/A
9
22898%
Biotechnology & Life Sciences
Healthcare
FR
Loos
